BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

541 related articles for article (PubMed ID: 32015295)

  • 1. Prostate Cancer: Prostate-specific Membrane Antigen Positron-emission Tomography/Computed Tomography or Positron-emission Tomography/Magnetic Resonance Imaging for Staging.
    Ferraro DA; Burger IA
    Top Magn Reson Imaging; 2020 Feb; 29(1):59-66. PubMed ID: 32015295
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study.
    Lenis AT; Pooli A; Lec PM; Sadun TY; Johnson DC; Lebacle C; Fendler WP; Eiber M; Czernin J; Reiter RE; Calais J
    Eur Urol Oncol; 2022 Oct; 5(5):544-552. PubMed ID: 32958451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Head-to-head Comparison of the Diagnostic Accuracy of Prostate-specific Membrane Antigen Positron Emission Tomography and Conventional Imaging Modalities for Initial Staging of Intermediate- to High-risk Prostate Cancer: A Systematic Review and Meta-analysis.
    Chow KM; So WZ; Lee HJ; Lee A; Yap DWT; Takwoingi Y; Tay KJ; Tuan J; Thang SP; Lam W; Yuen J; Lawrentschuk N; Hofman MS; Murphy DG; Chen K
    Eur Urol; 2023 Jul; 84(1):36-48. PubMed ID: 37032189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Five-year trends of bone scan and prostate-specific membrane antigen positron emission tomography utilization in prostate cancer: A retrospective review in a private centre.
    Haran C; McBean R; Parsons R; Wong D
    J Med Imaging Radiat Oncol; 2019 Aug; 63(4):495-499. PubMed ID: 30972933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
    Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
    Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prostate-specific membrane antigen positron emission tomography (PSMA PET) for urologists-when and which tracer?].
    Berliner C; Kesch C; Fendler WP; Eiber M; Maurer T
    Urologe A; 2022 Apr; 61(4):384-391. PubMed ID: 35138414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-effective in Prostate Cancer: An Analysis Informed by the proPSMA Trial.
    de Feria Cardet RE; Hofman MS; Segard T; Yim J; Williams S; Francis RJ; Frydenberg M; Lawrentschuk N; Murphy DG; De Abreu Lourenco R
    Eur Urol; 2021 Mar; 79(3):413-418. PubMed ID: 33341285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
    Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N
    BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imaging Prostate Cancer With Prostate-Specific Membrane Antigen PET/CT and PET/MRI: Current and Future Applications.
    Hope TA; Afshar-Oromieh A; Eiber M; Emmett L; Fendler WP; Lawhn-Heath C; Rowe SP
    AJR Am J Roentgenol; 2018 Aug; 211(2):286-294. PubMed ID: 29949419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Impact of 68Ga-PSMA PET/CT and PET/MRI on the Management of Prostate Cancer.
    Hoffmann MA; Wieler HJ; Baues C; Kuntz NJ; Richardsen I; Schreckenberger M
    Urology; 2019 Aug; 130():1-12. PubMed ID: 30986486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New frontiers in prostate cancer imaging: clinical utility of prostate-specific membrane antigen positron emission tomography.
    Afaq A; Batura D; Bomanji J
    Int Urol Nephrol; 2017 May; 49(5):803-810. PubMed ID: 28197764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of Ga
    Tarr GP; Kashyap P; Dixit DD; Willams AK; Koya MP; Lim R
    J Med Imaging Radiat Oncol; 2020 Feb; 64(1):78-86. PubMed ID: 31885207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identifying the Best Candidates for Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as the Primary Staging Approach Among Men with High-risk Prostate Cancer and Negative Conventional Imaging.
    Ma TM; Gafita A; Shabsovich D; Juarez J; Grogan TR; Thin P; Armstrong W; Sonni I; Nguyen K; Lok V; Reiter RE; Rettig MB; Steinberg ML; Kupelian PA; Yang DD; Muralidhar V; Chu C; Feng F; Savjani R; Deng J; Parikh NR; Nickols NG; Elashoff D; Czernin J; Calais J; Kishan AU
    Eur Urol Oncol; 2022 Feb; 5(1):100-103. PubMed ID: 33602654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate specific membrane antigen positron emission tomography in primary prostate cancer diagnosis: First-line imaging is afoot.
    Jiao J; Zhang J; Li Z; Wen W; Cui C; Zhang Q; Wang J; Qin W
    Cancer Lett; 2022 Nov; 548():215883. PubMed ID: 36027998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ga-PSMA PET/CT Staging of Newly Diagnosed Intermediate- and High-Risk Prostate Cancer.
    Kuten J; Mabjeesh NJ; Lerman H; Levine C; Barnes S; Even-Sapir E
    Isr Med Assoc J; 2019 Feb; 21(2):100-104. PubMed ID: 30772960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography in the Primary Staging of Newly Diagnosed Prostate Cancer: A Systematic Review of the Literature.
    Abrams-Pompe RS; Fanti S; Schoots IG; Moore CM; Turkbey B; Vickers AJ; Walz J; Steuber T; Eastham JA
    Eur Urol Oncol; 2021 Jun; 4(3):370-395. PubMed ID: 33272865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic Performance of Prostate-specific Membrane Antigen Positron Emission Tomography-targeted biopsy for Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis.
    Kawada T; Yanagisawa T; Rajwa P; Sari Motlagh R; Mostafaei H; Quhal F; Laukhtina E; Aydh A; König F; Pallauf M; Pradere B; Ceci F; Baltzer PAT; Hacker M; Rasul S; Karakiewicz PI; Araki M; Nasu Y; Shariat SF
    Eur Urol Oncol; 2022 Aug; 5(4):390-400. PubMed ID: 35715320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unexpected significant findings non-related to prostate cancer identified using combined prostate-specific membrane antigen positron emission tomography/CT and diagnostic CT scan in primary staging for prostate cancer.
    McEwan L; McBean R; Yaxley J; Wong D
    J Med Imaging Radiat Oncol; 2019 Jun; 63(3):318-323. PubMed ID: 30840361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.